Treatment of BRAF -V600E mutant metastatic colorectal cancer: new insights and biomarkers.

Javier RosMarta Rodríguez-CastellsNadia SaoudiIosune BaraibarFrancesc SalvaJosep TaberneroElena Élez

Published in: Expert review of anticancer therapy (2023)

There is a crucial need to better understand tumor biology and develop accurate and reliable biomarkers to enhance the antitumor activity of encorafenib-based combinations. The RNF43 mutation is an accurate and reliable predictive biomarker of response, and combinations that target crosstalk between the MAPK pathway, the immune system, and WNT pathways seem promising.

Keyphrases

metastatic colorectal cancer
high resolution
signaling pathway
stem cells
cell proliferation
wild type
pi k akt
combination therapy
mass spectrometry
dna damage response
replacement therapy
smoking cessation